Journal of Clinical Case Reports

Department of Cardiology, Endocrinology and Nephrology, Nordsjælland (North Zealand) University Hospital, Hillerød and Frederikssund, Denmark

Publications

• Review   
  Developing Deep Venous Thrombosis while on Rivaroxaban: A Review of Rivaroxaban
  Author(s): Rasha A. Al-Khafaji*
  
  Rivaroxaban is a Direct Oral Anticoagulant (DOAC), which has six licensed indications, including the use for prevention of stroke and systemic embolism with non-valvular Atrial Fibrillation (AF) and the treatment of Venous Thromboembolism (VTE). The pharmacokinetics and the pharmacogenetics of rivaroxaban are reviewed by the author because of a previously reported case of a 43-year-old Caucasian female, who was diagnosed with popliteal and calf Deep Venous Thrombosis (DVT) while on anticoagulation treatment in the form of rivaroxaban 20 mg PO daily. This treatment was started because of a previously verified bilateral Pulmonary Embolism (PE) 5 months earlier. Rivaroxaban is more frequently used in clinical practice, and many physicians are aware that rivaroxaban requires adaptation mainly on the patient's renal function. However, there is still a need to increase awareness of riva.. Read More»
  DOI: 10.37421/jccr.2020.10.1365

  Abstract HTML PDF